drugset
drugset / Trial / NCT02634788

Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

NCT02634788 ↗

Phase 3 Completed 322 enrolled INSYS Therapeutics Inc
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this trial is to evaluate analgesic efficacy of Buprenorphine Sublingual (under the tongue) Spray compared with placebo in participants with postoperative pain after bunionectomy.

Timeline

Start
2016-01-29
Primary completion
2016-06-24
Completion
2016-06-24

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 0.125 mg Other
Subject Buprenorphine Other / unclassified 0.25 mg Other
Subject Buprenorphine Other / unclassified 0.5 mg Other

Indications

No indication recorded.